Keyphrases
Mantle Cell Lymphoma
100%
POD24
100%
High Risk
33%
Clinical Course
33%
Risk Markers
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Prognostic Value
33%
Risk Score
33%
Combination Chemotherapy
33%
Prognostic Impact
33%
5-year Survival
33%
Disease Progression
33%
Lymphoma
33%
TP53 mutation
33%
Novel Therapies
33%
Mantle Cell Lymphoma International Prognostic Index
33%
Median Overall Survival
33%
Standard of Care
33%
Chemotherapy Regimen
33%
Salvage Therapy
33%
Median Progression-free Survival
33%
Cytarabine
33%
High-risk Features
33%
Line of Therapy
33%
Incurable Disease
33%
Long Response
33%
Bendamustine-rituximab
33%
Last Line
33%
Blastoids
33%
Cell Proliferation Markers
33%
Medicine and Dentistry
Disease
100%
Overall Survival
100%
Mantle Cell Lymphoma
100%
Disease Course
50%
Biological Marker
50%
Cell Proliferation
50%
Rituximab
50%
Progression Free Survival
50%
Mantle Cell Lymphoma International Prognostic Index
50%
Group Trial
50%
Combination Chemotherapy
50%
Salvage Therapy
50%
Chemotherapy Regimens
50%
Cytarabine
50%
Stem Cell Transplant
50%
Bendamustine
50%
Pharmacology, Toxicology and Pharmaceutical Science
Mantle Cell Lymphoma
100%
Disease
66%
Overall Survival
66%
Disease Course
33%
Biological Marker
33%
Progression Free Survival
33%
Rituximab
33%
Group Trial
33%
Chemotherapy Regimens
33%
Cytarabine
33%
Bendamustine
33%